In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30013058.
- Also identified by DOI 10.1038/s41467-018-04572-3 and PMC identifier 6048166.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Genetic aberrations driving pro-oncogenic and pro-metastatic activity remain an elusive target in the quest of precision oncology. To identify such drivers, we use an animal model of KRAS-mutant lung adenocarcinoma to perform an in vivo functional screen of 217 genetic aberrations selected from lung cancer genomics datasets. We identify 28 genes whose expression promoted tumor metastasis to the lung in mice. We employ two tools for examining the KRAS-dependence of genes identified from our screen: 1) a human lung cell model containing a regulatable mutant KRAS allele and 2) a lentiviral system permitting co-expression of DNA-barcoded cDNAs with Cre recombinase to activate a mutant KRAS allele in the lungs of mice. Mechanistic evaluation of one gene, GATAD2B, illuminates its role as a dual activity gene, promoting both pro-tumorigenic and pro-metastatic activities in KRAS-mutant lung cancer through interaction with c-MYC and hyperactivation of the c-MYC pathway.
Medical subject headings
- Adenocarcinoma of Lung
- GATA Transcription Factors
- Gene Expression Regulation, Neoplastic
- Lung Neoplasms
- Proto-Oncogene Proteins c-myc
- Proto-Oncogene Proteins p21(ras)